Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), MUC16 modulators(Mucin-16 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 14 Mar 2024 |